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Alteration of the p53 tumour-suppressor gene is the most common
genetic change found so far in malignancy (Hollstein et al, 1991),
including breast cancer (Osborne et al, 1991). The p53 gene is of
crucial importance for growth regulation, and it is therefore not
surprising that p53 alterations are consistently associated with
more aggressive tumour biological factors and poorer prognosis in
breast cancer (Davidoff et al, 1991a; Ostrowski et al, 1991; Hanzal
et al, 1992; Isola et al, 1992; Thor et al, 1992; Allred et al,
1993a,b; Barnes et al, 1993; Noguchi et al, 1993; Silvestrini et al,
1993; Stenmark-Askmalm et al, 1994).
Autoantibodies against p53 have been detected in sera from
breast cancer patients with prevalences ranging from 1% to 48%
(Crawford et al, 1982; Davidoff et al, 1991a, 1992; Schlichtholz et
al, 1992; Green et al, 1994; Mudenda et al, 1994; Porzolt et al,
1994; Lubin et al, 1995; Peyrat et al, 1995; Vojtesek et al, 1995;
Coomber et al, 1996; Regidor et al, 1996; Willsher et al, 1996). In
the study of Vojtesek et al 1995, which utilized three different
methods to detect anti-p53 antibodies [immunoprecipitation of
labelled protein, Western blotting and enzyme-linked immuno-
sorbent assay (ELISA)], p53-specific circulating antibodies,
confirmed by all methods, could be detected in only 1 of 100 cases
(1%). With ELISA, 25% of the sera were considered positive,
which was thought to be due to cross-reactions with unspecific
immunogens. In the other studies, using ELISA-based methods,
the reported frequency of positive sera has been in the range
12–48%. In most of these studies, the results were validated by
immunoprecipitation or Western blotting.
Antibodies can be detected against mutated as well as wild-type
p53 (Labrecque et al, 1993). Mutated p53 tends to have a much
longer half-life than wild-type p53, leading to accumulation of the
protein (Davidoff et al, 1991b). One study reported that there was
a significant correlation between presence of p53 autoantibodies
and the detection of mutated p53 protein in tissue sections
(Mudenda et al, 1994). That study also reported a much higher
detection rate of antibodies in patients with breast cancer than in
normal control volunteers. There are also observations indicating
that only tumours with missense mutations of p53, resulting in p53
overexpression, elicit p53 antibodies (Davidoff et al, 1992; Winter
et al, 1992; Lubin et al, 1993; Houbiers et al, 1995). Anti-p53 anti-
bodies have also been reported to indicate a poor prognosis in
patients with breast cancer (Schlichtholz et al, 1992; Mudenda et
al, 1994; Peyrat et al, 1995).
The objectives of the present study were to use an elaborate
epidemiological approach to evaluate whether breast cancer
patients do have an increased presence of p53 autoantibodies in
comparison with matched controls selected from a population-
based blood bank, and to investigate whether there was any corre-
lation between antibody responses towards p53 and the stage at
diagnosis as well as the survival of patients with breast cancer.
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Summary To perform an epidemiological evaluation of the predictive value of p53 autoantibodies in breast cancer, we measured antibodies
against p53 in serum samples from 165 breast cancer patients in comparison with serum samples from 330 healthy controls, selected from
the same population as the cases and matched for age, sex and specimen storage time. Median age of patients was 51 years (range 25–64
years). Presence of serum p53 autoantibodies was analysed by enzyme-linked immunosorbent assay (ELISA) and confirmed by Western
blotting. The lower ELISA reactivities were similar for cases and controls, but presence of high-level reactivity was more common among
cases than among controls [odds ratio (OR) 9.03, 95% confidence interval (CI) 2.40–50.43]. Presence of Western blot-detected p53
autoantibodies had a very similar association (OR 10.8, CI 3.0–59.4). Among the cases, we also studied whether there was any correlation
between level of anti-p53 antibodies and stage of the disease or survival. There was no significant correlation between presence of antibodies
and stage of the disease. There was a significant negative correlation between presence of p53 antibodies and survival (P = 0.003). A
stepwise multivariate Cox regression analysis showed that T-stage, age and presence of anti-p53 antibodies were significant independent
prognostic variables, with a dose-dependent negative effect on survival for all three variables. We conclude that presence of anti-p53
antibodies are of significance both for the risk of having breast cancer and the risk of dying from breast cancer.
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Patients and controls
The case material consisted of 165 consecutive patients with
newly diagnosed breast cancer admitted to the department of
surgery at the University hospital of Umeå, between 1985 and
1992. Umeå University Hospital is the only hospital providing
specialized breast cancer care for the population of the
Västerbotten county in Northern Sweden. To obtain comparability
with controls (see below), we excluded patients of age, at blood
sampling, over 65 years. The age of the patients was thus 25–
64 years (median 51 years). The tumours were clinically and
pathologically staged using the TNM classification according to
UICC (1982). In the majority of cases, treatment consisted of
breast conserving surgery followed by radiotherapy of the breast
and, in some cases, also the ipsilateral axilla. Patients with metas-
tases in the axillary lymph nodes and/or stage T3 also received
adjuvant therapy with tamoxifen or cytostatics. Patients with
relapse or progression later in the course of disease were treated
according to different protocols, mostly with cytostatics and/or
hormonal regimens. Some patients received radiotherapy to
metastatic sites. The patients were followed from date of diagnosis
until death (from all causes), or to completion of follow-up (3 Nov
1995). Thus, the follow-up time was 1–120 months (median 73
months). No patient was lost to follow-up.
Pretreatment serum samples were, after informed consent, taken
consecutively from all patients. The samples were frozen and
stored at –80°C.
For each case (n= 165), two controls were selected from the
blood bank connected with the Västerbotten Project, which is a
project offering health controls for the entire population of
Västerbotten county in the age range 30–60 years. Currently,
samples from about 50000 subjects have been collected and
stored at –80°C. The controls (n= 330) were matched for gender
and age at blood sampling (±3 years). To assure storage times for
cases and controls were as comparable as possible, we attempted
to match also for time of sampling. For 55% of the triplets, this
difference in sampling time between case and each of the corre-
sponding two controls was less than 3 years, but for the rest of the
material the difference was larger, up to 10 years at most.
Serology
Levels of antibodies against p53 were analysed by ELISA using
p53 protein, purified as described previously (Ryder et al, 1996).
Analyses were performed with the analysing laboratory blinded
to case–control status of the specimens. Cases and controls
belonging to the same triplet were analysed together, minimizing
the risk of bias due to possible interassay variations of the analysis
procedure.
The p53 preparation used for ELISA assays was analysed by
sodium dodecyl sulphate (SDS) polyacrylamide gel electro-
phoresis on a 10–15% gradient gel, followed by silver staining, to
verify its purity and that it had not been degraded in transit. A
major p53 band was detected (see Figure 1). p53 was coated onto
ELISA plates (Costar, Cambridge, MA, USA) at 0.4mg ml–1 (the
lowest coating concentration that gave maximal absorbance with
reactive sera) in 0.1Mtris-HCl, pH 8.8, and incubated at 4°C
overnight. After blocking with 10% horse serum in phosphate-
buffered saline (PBS) for 1h at 37°C, human sera [diluted 1:100 in
10% horse serum in PBS (HS-PBS)] was incubated on the plates
for 2h at 37°C. After washing with PBS/0.05% Tween 20 (PBS-
T), a mouse monoclonal antibody to human IgG (gamma chain)
(Eurodiagnostika, Malmö, Sweden), diluted 1:800 in HS-PBS,
was incubated on the plates for 90min at 37°C. After washing
with PBS-T, a horseradish peroxidase conjugated antibody to
mouse IgG (Southern Biotechnology) was incubated on the plates
for 1h at 37°C. After washing with PBS-T, the peroxidase
substrate ABTS (Boehringer) was incubated on the plates for 1h,
whereafter the levels of absorbance were recorded at 405nm.
For 96 sera (case–control triplets with two controls per case),
the in-house optimized ELISA method was compared with a
commercial p53 autoantibody detection kit (Dianova, Hamburg,
Germany). The absorbances of reactive sera were similar by both
methods.
Western blot
All serum samples with ELISA absorbances of 0.180 or more and
some randomly chosen sera with lower reactivity, in total 48 serum
samples, were also analysed for p53 reactivity by Western blot.
Forty microgram per gel of p53 was run on 10–15% polyacryl-
amide gradient gels in a semiautomatic gel electrophoresis system
(Phast system, Pharmacia, Uppsala, Sweden). The proteins of the
gels were transferred to nitrocellulose sheets, which were cut into
15 strips per gel. The strips were blocked in 5% non-fat dry milk in
PBS for 1h, incubated with the human sera [diluted 1:100 in 2%
non-fat dry milk in PBS (Whatman filtered)] for 2h at room
temperature, washed with 5% milk for 40min with three changes
of wash fluid, incubated with rabbit anti-human IgG-horseradish
peroxidase conjugate (Dako, Copenhagen, Denmark) [diluted
1:1000 in 2% non-fat dry milk in PBS (Whatman filtered)] for
30min at room temperature and then washed with PBS containing
0.5% Tween 20 for 2h with ten changes of washing fluid. The
strips were then developed using enhanced chemoluminescence as
described by the manufacturer (Amersham-Pharmacia, Uppsala,
Sweden).
Statistical methods
Statistical analyses were carried out after division of antibody
levels into three groups. The mean of the case mean and control
mean was used as lower cut-off, and the mean of the controls plus
two standard deviations as upper cut-off.
Multivariate conditional logistic regression for stratified data
was used to calculate odds ratios with age at blood sampling, cate-
gorized into the three groups 25–49, 50–59 and 60–64 years, and
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Table 1Distribution of antibody levels against p53 among breast cancer
patients and controls
Controls Cases
p53 Cut-off Number % Number % ORa 95% CIb
0–152 294 89 129 78 1.00
153–291 33 10 24 15 1.88 0.96–3.69
³292 3 1 12 7 9.03 2.40–50.43
Total 330 100 165 100
aOdds ratio; bconfidence interval.antibody levels, categorized as described above, in the model.
Exact confidence intervals for odds ratios were calculated using
the permutational distribution of the sufficient statistics.
Associations between antibody levels and T-, N- and M-stage of
the disease were tested with the Jonckheere–Terpstra test.
Kaplan–Meier estimate of survival and the log-rank test for
trend was used to compare survival for different groups of anti-
body levels.
A multivariate Cox regression model was used to study prog-
nosis in relation to antibody levels together with other prognostic
factors. As explanatory variables, antibody level, categorized into
three groups as explained above, T-stage (T1, T2 and T3), N-stage
(N– and N+), M-stage (M– and M+) and age at diagnosis, catego-
rized into the three groups 25–49, 50–59 and 60–64 years, were
used. Antibody level and age at diagnosis were included in the
model as categorical variables with the lowest group as reference
category. Backward stepwise analysis was used to select the final
model.
RESULTS
Anti-p53 antibodies in relation to breast cancer risk
The distribution of antibody levels against p53 in cases and
controls is shown in Table 1 and Figure 2. For cases and controls,
the median absorbance values were 0.115 and 0.109, respectively,
whereas the mean values were 0.198 and 0.106 respectively. The
reason for the discrepancy between median and mean was the
presence of a few patients with very high values. This skewness is
Antibodies against p53 in breast cancer929
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Table 2Distribution of antibody levels against p53 among cases of breast cancer for different T-, N- and M-stage
p53
0–152 153–291 ³292 Total
Number % Number % Number % Number % P-valuea
T-stageb
T1 55 80 9 13 5 7 69 100
T2 60 76 12 15 7 9 79 100
T3 4 67 2 33 0 0 6 100
Totalc 119 77 23 15 12 8 154 100 0.50
N-stageb
N– 47 82 5 9 5 9 57 100
N+ 51 73 12 17 7 10 70 100
Totalc 98 77 17 13 12 9 127 100 0.26
M-stageb
M– 86 81 12 11 8 8 106 100
M+ 5 83 0 0 1 17 6 100
Totalc 91 81 12 11 9 8 112 100 1.00
aJonckheere–Terpstra test; bpathologically staged; cbased on total number of adequately investigated patients.
Table 3Multivariate Cox regression analysis. Lowest level chosen as
reference for each variable
Variable RRa 95% CIb
p53
0–152 1.00
153–291 3.87 1.64–9.09
³291 5.00 1.77–14.11
T-stagec
T1 1.00
T2 5.05 1.90–13.37
T3 28.49 7.06–114.91
Age at diagnosis
25–49 1.00
50–59 1.98 0.74–5.31
60–64 5.45 1.99–14.92
aRelative risk; bconfidence interval; cpathologically staged.
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Figure 1Analysis of homogeneity of the p53 protein preparation by SDS-
polyacrylamide gel electrophoresis and silver staining. About 200ng of
protein was applied to a 10–15% polyacrylamide gradient gel. The positions
of the molecular weight markers are indicated on the leftevident in the highest quartile, in which 30% of cases and 21% of
controls were found. This discrepancy between cases and controls
was, furthermore, confined to the highest values.
Lower and upper cut-off points for antibody levels were 0.152
and 0.291 respectively. In the logistic regression analysis, age at
blood sampling did not have a significant effect, and removing it
from the model yielded estimated odds ratios of 1.88 (95% confi-
dence interval 0.96–3.69) and 9.03 (95% confidence interval
2.40–50.43) for the middle and upper groups of p53 antibodies
compared with the lowest group respectively (Table 1). Dividing
the material at the lower cut-off point yielded an odds ratio of 2.60
(95% confidence interval 1.44–4.80) for those above compared
with those under the cut-off value.
All sera with ELISA absorbances of 0.180 or more were also
analysed by the confirmatory method, Western blotting (Figure 3).
Most reactivities detected with the p53 band were very strong.
Among the sera with ELISA absorbances above the high cut-off
level (0.291), the reactivity was confirmed by Western blotting for
all subjects except one. In the OD range 0.250–0.291, a p53
Western blot reactivity was detected in three out of six serum
samples. In the OD range 0.180–0.249, a p53 Western blot reac-
tivity was detected only in 1 out of 20 serum samples. The breast
cancer risk associated with Western blot confirmed presence of
p53 autoantibodies was similar to that of the ELISA high cut-off-
detected p53 autoantibodies (3 out of 330 controls; 15 out of 165
cases; OR, 10.9; CI, 3.0–59.4).
Estimated odds ratios did not change significantly after
excluding the 96 case–control triplets in which the age difference
between case and control was more than 3 years, or the date of
blood sampling differed by more than 3 years.
Anti-p53 antibodies in relation to disease status
There was no significant correlation between serum level of p53
antibodies and T-, N- or M-stage of the disease (Table 2). Western
blot reactivity was also not significantly associated with the T-, N-
or M-stage of the disease (not shown).
Anti-p53 antibodies in relation to prognosis
The univariate survival analysis was based on 165 cases, of which
54 were observed to die during follow-up. Survival was correlated
with anti-p53 antibody level; the higher the antibody level, the
shorter was the survival. Mean survival was 97, 73 and 71 months
for the low, middle and upper group of antibody levels respec-
tively. In Figure 4, the Kaplan–Meier estimate of the survival
distributions is shown for each group of antibody levels. The log-
rank test for trend showed a significant difference (P = 0.003) in
survival between the groups.
The multivariate survival analysis was based on 99 cases with
complete data on all variables. Of these cases, 35 were observed to
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Figure 2 Box plots showing the distribution of serum antibodies to p53
antigens for breast cancer patients and controls. The boundaries of the
boxes represent 25% and 75% of the values, the lines in the boxes represent
the median values and the lines connected to the boxes by vertical bars
indicate the range of non-extreme values
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Figure 3 Detection of serum antibodies to p53 by Western blotting. Nine
nitrocellulose strips with the p53 protein preparation have been used to test
nine different human sera for presence of serum IgG reactive with p53, as
described in the Materials and methods section. The positions of the
molecular weight markers are indicated on the left. Serum samples number
1, 2, 5, 6 and 8 were scored as p53 antibody positive, whereas serum
samples 3, 4, 7 and 9 were scored as negative
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Figure 4 Kaplan–Meier estimates of survival distributions for each group of
antibody levels. Each mark on the curves represents a censoring timedie during follow-up. The backward stepwise strategy in the multi-
variate Cox regression model with inclusion of stage (T-, N- and
M-stage respectively), age at diagnosis and antibody level
revealed that T-stage, age at diagnosis and antibody level remained
as significant independent prognostic variables (Table 3). The rela-
tive risk estimates for different levels of the variables indicate the
presence of a dose-dependent effect on survival for both level of
anti-p53 antibodies and T-stage, besides age. Inclusion of Western
blot-detected p53 autoantibodies instead of ELISA-detected p53
autoantibodies in the multivariate model also found that presence
of anti-p53 autoantibodies had a significant independent effect on
prognosis. The point estimate for the Western blot-detected p53
antibodies was 2.86 (CI, 1.13–7.26), which is somewhat lower
than, albeit not statistically significantly different from, the prog-
nostic value of presence of ELISA-detected p53 autoantibodies.
DISCUSSION
The main finding of the present study was that a high serum level
of antibodies directed against p53 was found more often in breast
cancer cases than in age- and sex-matched normal subjects from
the general population. In patients with breast cancer, presence of
p53 autoantibodies also indicated a shortened survival. In this
study, a population-based reference material was utilized, which
is advantageous from an epidemiological point of view. To our
knowledge, a population-based selection of controls has not been
used in previous studies.
The finding of serum p53 autoantibodies in breast cancer is
consistent with other studies. The first was Crawford et al (1982),
who reported 9% p53-positive sera in 155 breast cancer patients
by immunoprecipitation whereas none was positive among 164
healthy controls. Mudenda et al (1994) detected significantly
higher antibody levels in breast cancer patients than in normal
control volunteers with ELISA methodology. In the present study,
population-based controls were used, matched for sex, age and time
of specimen storage. The difference in anti-p53 antibody levels,
measured with an ELISA-based method, was smaller between
cases and controls in this study. Nevertheless, the difference was
clearly evident for subjects with the highest absorbance levels of
anti-p53 serum antibodies (absorbance values above 0.292), which
correlated closely with the presence of p53 autoantibodies
detectable also by Western blotting. Presence of ELISA reactivity
that was not confirmed by Western blotting could be non-specific,
directed against p53 conformational epitopes destroyed by dena-
turing in Western blotting or present in too low amounts to be
detectable by the less sensitive Western blot technique. The fact
that this low-level p53 ELISA reactivity (<0.297 absorbance) was
significantly different from the reference group only in the prog-
nostic analysis, but not in the case–control analysis, suggests a
substantial unspecific component, the result of which is that a
substantial positive predictive value of this low reactivity is only
found in the high-prevalence population (the cases).
p53 in tumour tissue has been clearly demonstrated as a prog-
nostic marker in breast cancer (Davidoff et al, 1991a; Ostrowski
et al, 1991; Hanzal et al, 1992; Isola et al, 1992; Thor et al, 1992;
Allred et al, 1993a, b; Barnes et al, 1993; Noguchi et al, 1993;
Silvestrini et al, 1993; Stenmark-Askmalm et al, 1994). Increased
p53 protein amounts in tumour cells are indicative of mutated p53
(Davidoff et al, 1991b). An increase of p53 protein in tumours may
elicit an immunological response (Winter et al, 1992), and there-
fore the finding of an association between serological anti-p53
response and survival in breast cancer is not surprising and has
also been made by others (Peyrat et al, 1995). The multivariate
analysis indicated that anti-p53 antibody level is an independent
prognostic variable. The impact on survival by anti-p53 antibodies
was not dependent on covariation with stage, which was also indi-
cated by the lack of correlation between level of anti-p53 anti-
bodies and clinical stage. This observation has also been made by
other investigators (Schlichtholz et al, 1992; Peyrat et al, 1995),
who found no significant correlation between p53 antibodies and
clinical stage.
A question of great relevance from a theoretical and tumour
biological point of view is when in the natural course of breast
cancer the p53 mutation is operative. In some cancers, including
breast, alterations in p53 have been shown to be an early event
(reviewed in Lane et al, 1990). Anti-p53 antibodies have been
detected before the diagnosis of breast cancer in 4 of 36 women
with a positive history of breast cancer (Green et al, 1994).
However, whether anti-p53 antibodies may be used as tumour
markers in screening for breast cancer seems highly questionable.
In addition, the present study and others (Schlichtholz et al,
1992; Mudenda et al, 1994; Peyrat et al, 1995) demonstrate that
presence of p53 autoantibodies is indicative of a worsened prog-
nosis. Perhaps p53 mutation could be viewed as an event that
speeds up the disease development, and thus be regarded as a
marker for a more aggressive behaviour of the tumour (Davidoff et
al, 1991). It would, thus, be of interest to sample serum consecu-
tively from breast cancer patients during the course of the disease,
as well as sera taken before the diagnosis of breast cancer was
made, and to correlate any p53 antibody elevation with the appear-
ance of the disease, any recurrence of the disease, or other signs of
aggravation of the disorder. Because the blood sampling and sero-
logical analysis of p53 antibodies are rather simple procedures, the
methodology may have a potential as a prognostic marker in breast
cancer in the future.
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